Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: CYS Investments, Inc. Announces First Quarter 2013 Financial Results to CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma

This site contains about 63,386 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   100   200   300   400   410   420   430   440   450   460   470   480   489   490   491   492   493   494   495   496   497   498   499   500   501   502   503   504   505   506   507   508   509   510   511   512   513   514   515   516   517   518   520   530   540   550   560   570   580   590   600   700   800   900   1,000   1,100   1,200   1,300   1,400   1,500   2,000   2,113 

2013/4/17
CYS Investments, Inc. Announces First Quarter 2013 Financial Results
CYS Investments, Inc. (NYSE: CYS) (“CYS” or the “Company”) today announced financial results for the quarter ended March 31, 2013.
View more CYS Investments, Inc. Announces First Quarter 2013 Financial Results analysis
Sign-up for CYS Investments, Inc. Announces First Quarter 2013 Financial Results investment picks
2013/4/23
CYS Investments, Inc. Announces Pricing of Public Offering of Series B Cumulative Redeemable Preferred Stock
CYS Investments, Inc. (NYSE: CYS) (the "Company") today announced that it priced an underwritten public offering of 8,000,000 shares of its 7.50% Series B Cumulative Redeemable Preferred Stock (the “Series B Preferred Stock”), liquidation preference $25.00 per share, for gross proceeds of $200 million, before deducting underwriting discounts and estimated offering expenses.
View more CYS Investments, Inc. Announces Pricing of Public Offering of Series B Cumulative Redeemable Preferred Stock analysis
Sign-up for CYS Investments, Inc. Announces Pricing of Public Offering of Series B Cumulative Redeemable Preferred Stock investment picks
2013/4/23
CYS Investments, Inc. Announces Public Offering of Series B Cumulative Redeemable Preferred Stock
CYS Investments, Inc. (NYSE: CYS) (the "Company") today announced that it plans to make a public offering of shares of its Series B Cumulative Redeemable Preferred Stock (the “Series B Preferred Stock”). The Company intends to apply to list the Series B Preferred Stock on the New York Stock Exchange under the symbol “CYS PrB.” Morgan Stanley & Co.
View more CYS Investments, Inc. Announces Public Offering of Series B Cumulative Redeemable Preferred Stock analysis
Sign-up for CYS Investments, Inc. Announces Public Offering of Series B Cumulative Redeemable Preferred Stock investment picks
2013/2/11
CYS Investments, Inc. Announces Record Date for 2013 Annual Meeting of Stockholders
CYS Investments, Inc. (NYSE: CYS) (the "Company") announced today that its Board of Directors has established March 8, 2013, as the record date for determining stockholders entitled to vote at the 2013 Annual Meeting of Stockholders.
View more CYS Investments, Inc. Announces Record Date for 2013 Annual Meeting of Stockholders analysis
Sign-up for CYS Investments, Inc. Announces Record Date for 2013 Annual Meeting of Stockholders investment picks
2013/3/8
CYS Investments, Inc. Board of Directors Declares First Quarter 2013 Common Stock Dividend of $0.32 Per Share, and Preferred Stock Dividend
The Board of Directors of CYS Investments, Inc. (NYSE: CYS) (the "Company") today declared a quarterly dividend of $0.32 per share of common stock for the first quarter of 2013.
View more CYS Investments, Inc. Board of Directors Declares First Quarter 2013 Common Stock Dividend of $0.32 Per Share, and Preferred Stock Dividend analysis
Sign-up for CYS Investments, Inc. Board of Directors Declares First Quarter 2013 Common Stock Dividend of $0.32 Per Share, and Preferred Stock Dividend investment picks
2013/4/29
CYS Investments, Inc. to Present at the JMP Securities Research Conference
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
View more CYS Investments, Inc. to Present at the JMP Securities Research Conference analysis
Sign-up for CYS Investments, Inc. to Present at the JMP Securities Research Conference investment picks
2013/5/2
CYS Investments, Inc. to Present at the Wells Fargo Securities Specialty Finance Conference
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
View more CYS Investments, Inc. to Present at the Wells Fargo Securities Specialty Finance Conference analysis
Sign-up for CYS Investments, Inc. to Present at the Wells Fargo Securities Specialty Finance Conference investment picks
2013/2/26
Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer
Cytori Therapeutics (NASDAQ: CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer.
View more Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer analysis
Sign-up for Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer investment picks
2013/3/28
Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells
Cytori Therapeutics (NASDAQ: CYTX) received US Patent No.
View more Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells analysis
Sign-up for Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells investment picks
2013/3/22
Cytori Provides Update in 510(k) Appeal Decision
Cytori Therapeutics (NASDAQ: CYTX) today announced that the United States Court of Appeals for the District of Columbia Circuit has ruled on the Company’s conjoined appeals (case no.
View more Cytori Provides Update in 510(k) Appeal Decision analysis
Sign-up for Cytori Provides Update in 510(k) Appeal Decision investment picks
2013/3/7
Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013
Cytori Therapeutics (NASDAQ: CYTX) reports its 2012 business and financial results and provides an outlook for 2013.
View more Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013 analysis
Sign-up for Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013 investment picks
2013/5/9
Cytori Reports First Quarter 2013 Business and Financial Results
Cytori Therapeutics (NASDAQ: CYTX) today reports its first quarter 2013 financial results and provides updates on clinical development and commercialization activities.
View more Cytori Reports First Quarter 2013 Business and Financial Results analysis
Sign-up for Cytori Reports First Quarter 2013 Business and Financial Results investment picks
2013/3/11
Cytori Therapeutics To Present at the 25th Annual Roth Conference on March 18
Cytori Therapeutics Inc. (NASDAQ: CYTX) will present and provide a corporate update from the 25 th Annual Roth Conference on Monday, March 18 at 4:30 PM PT.
View more Cytori Therapeutics To Present at the 25th Annual Roth Conference on March 18 analysis
Sign-up for Cytori Therapeutics To Present at the 25th Annual Roth Conference on March 18 investment picks
2013/4/10
Cytori to Present at Regen Med Investor Day 2013 on April 17
Cytori Therapeutics, Inc .
View more Cytori to Present at Regen Med Investor Day 2013 on April 17 analysis
Sign-up for Cytori to Present at Regen Med Investor Day 2013 on April 17 investment picks
2013/3/29
Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present and provide a webcast of their corporate presentation at BioCentury's 20 th Annual Future Leaders in the Biotech Industry conference at 8:30 AM (ET) on Friday, April 5, 2013 in New York.
View more Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013 analysis
Sign-up for Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013 investment picks
2013/5/2
Cytori to Webcast First Quarter Financial Results on May 9
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 9, 2013 at 5:00 PM Eastern Time.
View more Cytori to Webcast First Quarter Financial Results on May 9 analysis
Sign-up for Cytori to Webcast First Quarter Financial Results on May 9 investment picks
2013/2/28
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Thursday, March 7, 2013 at 5:00 PM Eastern Time.
View more Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7 analysis
Sign-up for Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7 investment picks
2013/4/8
CytoSorbents Announces Trauma Advisory Board
MONMOUTH JUNCTION, N.J., April 8, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO) , a critical care focused company using blood purification to treat life-threatening illnesses, today announced the establishment of its Trauma Advisory Board consisting of international leaders in the fields of trauma, trauma research, and critical care.
View more CytoSorbents Announces Trauma Advisory Board analysis
Sign-up for CytoSorbents Announces Trauma Advisory Board investment picks
2013/4/15
CytoSorbents Appoints Christopher Cramer as Vice President of Business Development
MONMOUTH JUNCTION, N.J., April 15, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO) , a critical care-focused company using blood purification to treat life-threatening illnesses in the intensive care unit, announced today that it has appointed Christopher Cramer, MS, MBA, as Vice President of Business Development.
View more CytoSorbents Appoints Christopher Cramer as Vice President of Business Development analysis
Sign-up for CytoSorbents Appoints Christopher Cramer as Vice President of Business Development investment picks
2013/2/8
CytoSorbents Appoints Ronald Berger as Interim Chief Financial Officer
MONMOUTH JUNCTION, N.J. , Feb.
View more CytoSorbents Appoints Ronald Berger as Interim Chief Financial Officer analysis
Sign-up for CytoSorbents Appoints Ronald Berger as Interim Chief Financial Officer investment picks
2013/4/11
CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract
MONMOUTH JUNCTION, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO) , a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, today announced the award of an additional Phase I Option SBIR (Small Business Innovation Research) contract by the US Army Medical Research and Materiel Command, valued at $50,000 over a 2 month period.
View more CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract analysis
Sign-up for CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract investment picks
2013/4/3
CytoSorbents Provides Corporate Update and Reports 2012 Year End Financial Results
MONMOUTH JUNCTION, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB:CTSO) , a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, provides a shareholder update and reports its financial results for the fiscal year ending December 31, 2012.
View more CytoSorbents Provides Corporate Update and Reports 2012 Year End Financial Results analysis
Sign-up for CytoSorbents Provides Corporate Update and Reports 2012 Year End Financial Results investment picks
2013/1/29
CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
MONMOUTH JUNCTION, N.J. , Jan.
View more CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers analysis
Sign-up for CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers investment picks
2013/3/13
CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference
MONMOUTH JUNCTION, N.J. , March 13, 2013 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO) , a critical care focused company using blood purification to treat life-threatening illnesses, announced that it will exhibit its European Union approved CytoSorb® cytokine reduction technology at the 33 rd International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium from March 19-22, 2013 .
View more CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference analysis
Sign-up for CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference investment picks
2013/3/5
CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital Forum on March 8, 2013
http://media.marketwire.com/attachments/201109/17963_CYTOLogo.jpeg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=993049&ProfileId=051205&sourceType=1 MONMOUTH JUNCTION, NJ --
View more CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital Forum on March 8, 2013 analysis
Sign-up for CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital Forum on March 8, 2013 investment picks
2013/4/23
CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a special protocol assessment (SPA) for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.
View more CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma analysis
Sign-up for CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma investment picks
2013/5/8
CytRx Provides Update on Clinical Programs
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced that it will focus on the clinical development of aldoxorubicin and expansion of its oncology pipeline based on its proprietary linker platform technology, following the recommendation of an independent Data Safety Monitoring Committee (DSMC) to discontinue the Phase 2b clinical trial with tamibarotene as a first-line treatment for patients with advanced non-small-cell lung cancer.
View more CytRx Provides Update on Clinical Programs analysis
Sign-up for CytRx Provides Update on Clinical Programs investment picks
2013/2/28
CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been completed in the Company’s global Phase 2b clinical trial with its oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). “Tamibarotene could represent a multi-billion dollar market opportunity as a breakthrough in the treatment of NSCLC,” said CytRx CEO Steven A.
View more CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer analysis
Sign-up for CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer investment picks
2013/1/31
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that the Data Safety Monitoring Committee overseeing the Company’s global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) has recommended conducting the clinical trial through completion.
View more CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer analysis
Sign-up for CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer investment picks
2013/5/6
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
CytRx Corporation (NASDAQ:CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that the independent Data Safety Monitoring Committee (DSMC) overseeing the Company’s international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion.
View more CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma analysis
Sign-up for CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: CYS Investments, Inc. Announces First Quarter 2013 Financial Results to CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.